Clinical trials: Demyelinating Disorder
Multiple Sclerosis
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
The primary objective is to determine whether prolonged-release fampridine (10 mg twice daily) has a clinically meaningful effect on participant-reported walking ability over a 24-week study period.
- Trial name
- ENHANCE (NCT02219932)
- Testing
- fampridine
- Where
- 87 sites in United States, Bulgaria and 9 more
- Volunteers
- 646 people
- Sponsor
- Biogen
Multiple Sclerosis
Tecfidera Slow-Titration Study
The primary objective of the study is to assess whether a 6-week titration (compared with a 1-week titration) is effective in reducing the incidence of dimethyl fumarate (DMF [Tecfidera])-related gastrointestinal (GI) adverse…
- Trial name
- TITRATION (NCT02428231)
- Testing
- dimethyl fumarate
- Where
- 20 sites in United States, Belgium and 2 more
- Volunteers
- 62 people
- Sponsor
- Biogen
Multiple Sclerosis
HFS (High-Fiber Supplement) in MS (Multiple Sclerosis)
Multiple sclerosis (MS) is an autoimmune disease directed against the Central Nervous System (CNS). Recent studies have indicated that changes in the gut microbiota are associated with disease initiation and progression.
- Trial name
- NCT04574024
- Testing
- NBT-NM108
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Suhayl Dhib-Jalbut, MD
Pain, Multiple Sclerosis
A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin
To investigate the ability of a cannabis based medicine extract to relieve chronic refractory pain of neurological origin.
- Trial name
- NCT01606176
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720
The study will assess the patients' satisfaction of treatment after 12 months treatment with fingolimod It also will assess the tolerability profile of fingolimod in a small population.
- Trial name
- NCT01578330
- Testing
- Fingolimod
- Where
- 11 sites in Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT01093326
- Testing
- Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg
- Where
- 71 sites in United States, Austria and 18 more
- Volunteers
- 353 people
- Sponsor
- Actelion
Multiple Sclerosis, Relapsing-Remitting
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
The purpose of this study was to establish the efficacy and safety of two different doses of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous interferon…
- Trial name
- CARE-MS II (NCT00548405)
- Testing
- Alemtuzumab 12 mg, Alemtuzumab 24 mg, Interferon beta-1a
- Where
- 191 sites in United States, Argentina and 21 more
- Volunteers
- 840 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis, Gait Disorders, Neurologic
Pilot Study of Powered Exoskeleton Use for Gait Rehabilitation in Individuals With Multiple Sclerosis
The investigator plans to test the use of the Ekso Bionics® Gait Training (Ekso GT™) exoskeleton for gait training in MS patients. The device will solely be used in the clinic under direct supervision from a physical therapist.
- Trial name
- NCT04000373
- Testing
- Ekso GT™ exoskeleton
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The Cleveland Clinic
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
The primary study objective is to test the superiority of Daclizumab High Yield Process (DAC HYP) compared to interferon β 1a (IFN β-1a) in preventing multiple sclerosis (MS) relapse in participants with relapsing remitting…
- Trial name
- (DECIDE) (NCT01064401)
- Testing
- BIIB019 (Daclizumab High Yield Process), Interferon beta-1a
- Where
- 228 sites in United States, Argentina and 26 more
- Volunteers
- 1,841 people
- Sponsor
- Biogen
Multiple Sclerosis
Memantine for Spasticity in MS Patients
Participants (n=20) will be identified at routine care visits performed at the Rochester Multiple Sclerosis Center. Eligible participants will have MS by McDonald Criteria,7 and will have a modified Ashworth spasticity rating8 of…
- Trial name
- NCT00638027
- Testing
- memantine
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Rochester
Multiple Sclerosis
tDCS and Glucose Uptake in Leg Muscles
This study is to examine the efficacy of tDCS to improving walking in people with Multiple Sclerosis (PwMS). Our study compromises 1 group of subjects with MS which will attend the lab for three sessions.
- Trial name
- NCT04016844
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Iowa
Relapsing-Remitting Multiple Sclerosis
Natalizumab (Tysabri) Re-Initiation of Dosing
The primary objectives for the initial treatment period of this study are to further evaluate the safety of natalizumab monotherapy by evaluating the risk of hypersensitivity reactions and immunogenicity following re-exposure to…
- Trial name
- STRATA (NCT00297232)
- Testing
- Natalizumab
- Where
- 112 sites in Australia, Belgium and 19 more
- Volunteers
- 1,094 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis
This is an open-label, multi-center, 12-week, randomized, controlled, parallel group, Phase 4 study to assess whether the morning administration of interferon beta 1a (Rebif®) leads to a lower severity of flu-like symptoms (FLS)…
- Trial name
- RELIEF (NCT02064816)
- Testing
- Rebif®
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Adrenoleukodystrophy, Metachromatic Leukodystrophy
Stem Cell Transplant for Inborn Errors of Metabolism
The purpose of this study is to determine the safety and engraftment of donor hematopoietic cells using this conditioning regimen in patients undergoing a hematopoietic (blood forming) cell transplant for an inherited metabolic…
- Conditions
- Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Gaucher's Disease
- Trial name
- NCT00176904
- Testing
- Stem Cell Transplant, Busulfan, Cyclophosphamide, Antithymocyte Globulin
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Relapsing-Remitting Multiple Sclerosis
Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
The primary objective of this study is to evaluate the effect of symptomatic therapies on gastrointestinal-related events reported by participants with relapsing-remitting multiple sclerosis initiating therapy with BG00012…
- Trial name
- TOLERATE (NCT02125604)
- Testing
- dimethyl fumarate
- Where
- 19 sites in Germany
- Volunteers
- 214 people
- Sponsor
- Biogen
Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
This is a prospective, multicenter, randomized, double-blind, placebo-controlled, parallel-group 3-arm study to investigate 2 different doses of subcutaneous (SC) IgPro20 compared with placebo for maintenance treatment of…
- Trial name
- NCT01545076
- Testing
- IgPro20 (low dose), IgPro10, IgPro20 (high dose)
- Where
- 91 sites in United States, Australia and 14 more
- Volunteers
- 208 people
- Sponsor
- CSL Behring
Relapsing Remitting Multiple Sclerosis
A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
The objectives of this study are to evaluate the utility of two gastrointestinal (GI) symptom scales (Individual GI Symptom and Impact Scale {IGISIS} and Global GI Symptom and Impact Scale {GGISIS}) in assessing GI tolerability…
- Trial name
- NCT03093324
- Testing
- ALKS 8700, Dimethyl Fumarate
- Where
- 67 sites in United States, Germany and 1 more
- Volunteers
- 506 people
- Sponsor
- Biogen
Multiple Sclerosis
The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)
The purpose of this study is to investigate the impact of ankle foot orthoses (AFOs) on the spatial and temporal gait parameters, electromyography (EMG), walking endurance, and quality of life in select individuals living with…
- Trial name
- NCT01947582
- Testing
- Ankle foot orthosis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Texas Southwestern Medical Center
Migraine, Headache
RELAXaHEAD for Headache Patients (Phase II)
The goal of this research is to assess the utility of smartphone-based progressive muscle relaxation (PMR) for the treatment of migraine and sleep.
- Conditions
- Migraine, Headache, Multiple Sclerosis, Insomnia
- Trial name
- NCT05466682
- Testing
- Smartphone-Based Progressive Muscle Relaxation Therapy (PMR), Monitored Usual Care (MUC)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- NYU Langone Health
CIDP, Chronic Inflammatory Demyelinating Polyneuropathy
Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
The purpose of the study is to examine if alpha lipoic acid is an effective treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).
- Trial name
- NCT00962429
- Testing
- lipoic acid
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Oregon Health and Science University